Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone

被引：30
作者：
Takalkar A. [1 ]
Adams S. [1 ]
Subbiah V. [2 ]
机构：
[1] PET Imaging Center, Biomedical Research Foundation of Northwest Louisiana, Shreveport, 71103, LA
[2] Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, 77030, TX
来源：
Experimental Hematology & Oncology | / 3卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Alpha particle; Bone metastases; Breast cancer; Exceptional responder; Outlier responder; Radium; 223; Unusual responder; Xofigo;
D O I：
10.1186/2162-3619-3-23
中图分类号：
学科分类号：
摘要：
Background: Hormone-refractory breast cancer metastatic to bone is a clinically challenging disease associated with high morbidity, poor prognosis, and impaired quality of life owing to pain and skeletal-related events. In a preclinical study using a mouse model of breast cancer and bone metastases, Ra-223 dichloride was incorporated into bone matrix and inhibited proliferation of breast cancer cells and differentiation of osteoblasts and osteoclasts (all P values < .001) in vitro. Ra-223 dichloride also induced double-strand DNA breaks in cancer cells in vivo.Methods: The US Food and Drug Administration recently approved radium-223 (Ra-223) dichloride (Ra-223; Xofigo injection) alpha-particle therapy for the treatment of symptomatic bone metastases in patients with castration-resistant prostate cancer. On the basis of a strong preclinical rationale, we used Ra-223 dichloride to treat bone metastases in a patient with breast cancer.Results: A 44-year-old white woman with metastatic breast cancer who was estrogen receptor-positive, BRCA1-negative, BRCA2-negative, PIK3CA mutation (p.His1047Arg) positive presented with diffuse bony metastases and bone pain. She had hormone refractory and chemotherapy refractory breast cancer. After Ra-223 therapy initiation her bone pain improved, with corresponding decrease in tumor markers and mixed response in 18F-FDG PET/CT and 18F-NaF bone PET/CT. The patient derived clinical benefit from therapy.Conclusion: We have shown that Ra-223 dichloride can be safely administered in a patient with hormone-refractory bone metastasis from breast cancer at the US FDA-approved dose for prostate cancer. Furthermore, because the treatment did not cause any drop in hematologic parameters, it has the potential to be combined with other radiosensitizing therapies, which may include chemotherapy or targeted therapies. Given that Ra-223 dichloride is already commercially available, this case report may help future patients and provide a rationale for initiating clinical research in the use of Ra-223 dichloride to treat bone metastasis from breast cancer. A randomized clinical trial is needed to provide evidence of efficacy, safety, and good outcomes. © 2014 Takalkar et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 10 条
  • [1] Sze W.M., Shelley M., Held I., Mason M., Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials, Cochrane Database Syst Rev, 2, (2004)
  • [2] Anderson P., Salazar-Abshire M., Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives, Curr Oncol Rep, 8, 6, pp. 415-422, (2006)
  • [3] Kluetz P.G., Pierce W., Maher V.E., Zhang H., Tang S., Song P., Liu Q., Haber M.T., Leutzinger E.E., Al-Hakim A., Chen W., Palmby T., Alebachew E., Sridhara R., Ibrahim A., Justice R., Pazdur R., Radium ra 223 dichloride injection: u.s. Food and drug administration drug approval summary, Clin Canc Res, 20, 1, pp. 9-14, (2014)
  • [4] Eckhardt B.L., Francis P.A., Parker B.S., Anderson R.L., Strategies for the discovery and development of therapies for metastatic breast cancer, Nat Rev Drug Discov, 11, 6, pp. 479-497, (2012)
  • [5] Baidoo K.E., Yong K., Brechbiel M.W., Molecular pathways: targeted alpha-particle radiation therapy, Clin Canc Res, 19, 3, pp. 530-537, (2013)
  • [6] Bruland O.S., Jonasdottir T.J., Fisher D.R., Larsen R.H., Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy, Current Radoipharmaceuticals, 1, 1, pp. 203-208, (2008)
  • [7] Bruland O.S., Nilsson S., Fisher D.R., Larsen R.H., High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?, Clin Canc Res, 12, 20, pp. 6250s-6257s, (2006)
  • [8] Parker C., Nilsson S., Heinrich D., Helle S.I., O'Sullivan J.M., Fossa S.D., Chodacki A., Wiechno P., Logue J., Seke M., Widmark A., Johannessen D.C., Hoskin P., Bottomley D., James N.D., Solberg A., Syndikus I., Kliment J., Wedel S., Boehmer S., Dall'Oglio M., Franzen L., Coleman R., Vogelzang N.J., O'Bryan-Tear C.G., Staudacher K., Garcia-Vargas J., Shan M., Bruland T., Sartor O., Et al., Alpha emitter radium-223 and survival in metastatic prostate cancer, New Engl J Med, 369, 3, pp. 213-223,
  • [9] Suominen M.I., Rissanen J.P., Kakonen R., Fagerlund K.M., Alhoniemi E., Mumberg D., Ziegelbauer K., Halleen J.M., Kakonen S.M., Scholz A., Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis, J Natl Canc Inst, 105, 12, pp. 908-916, (2013)
  • [10] Coleman R., Aksnes A.K., Naume B., Garcia C., Jerusalem G., Piccart M., Vobecky N., Thuresson M., Flamen P., A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease, Breast Canc Res Treat, 145, 2, pp. 411-418, (2014)
1